anocurcumin role in patients with breast and gastrointestinal cancer resistant to treatment

Phase 2

• Conditions: c50-c50 an; Breast and GI cancers.; Breast, unspecified; Malignant neoplasms of digestive organs

• Registration Number: IRCT2014091418745N2
• Lead Sponsor: Vice-?hancellor for Research of Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Randomize; Pathology report of invasive breast and GI carcinoma; signed informed consent; resistant to treatment; metastatic disease.

Exclusion criteria: Less than 50% heart ejection fraction; heart failure; liver failure (liver enzymes more than 5 times of upper normal limit) or creatinine more than 2 mg/dl; low albumin<2; brain metastasis; sever diarrhea.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Response to treatment. Timepoint: Before and after drug therapy, 3 months. Method of measurement: CT scan.

Secondary Outcome Measures

Name	Time	Method
The assesment of quality of life. Timepoint: Befor and after of treatment, 3 months. Method of measurement: Questionnaires of FACT and CARES.